

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

ANNOUNCEMENT

Guangzhou Pharmaceutical Company Limited (the “Company”) has been informed that Guangzhou Pharmaceutical Holdings Limited (“GPHL”), the controlling shareholder of the Company, received the civil ruling **【(2012)-Zhongmintezi No.7160】** (the “Civil Ruling”) dated 13 July 2012 from the Beijing No.1 Intermediate People’s Court* (北京市第一中級人民法院) (the “Court”) of the People’s Republic of China (the “PRC”).

Pursuant to the Civil Ruling, the ruling made by the Court regarding the application made by Hung To (Holdings) Company for revoking the arbitration ruling made by the China International Economic and Trade Arbitration Commission dated 9 May 2012 (please refer to the announcements of the Company dated 11 May 2012 and 4 June 2012 respectively for details) is as follow:

The application made by Hung To (Holdings) Company for revoking the arbitration ruling **【[2012] China Mao Zhong Jing Cai Zi No. 0240】** made by the China International Economic and Trade Arbitration Commission is dismissed. The Civil Ruling is final and conclusive.

The board of the directors of the Company (the “Board”) confirms that, other than the Civil Ruling, it is not in possession of information which the Company is required to disclose under the listing rules of the Shanghai Stock Exchange and the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (“Hong Kong Listing Rules”), nor is the Board aware of any information which may have any significant impact on the Company’s share price and is therefore discloseable under the listing rules of the Shanghai Stock Exchange or the Hong Kong Listing Rules.

The Company’s designated media for publication of its information includes Shanghai Securities News, Securities Times, the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to pay attention to investment risks.

This announcement is made pursuant to Rule 13.09(2) of the Hong Kong Listing Rules.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 15 July 2012

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.